Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.04
Nov 17 • 3:59 PM ET Dollar change+0.03 Percentage change(1.49%)
Aftermarket Close
2.04
Aftermarket • 6:54 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
161.57M
Enterprise Value
94.14M
Income
10.24M
Sales
122.29M
Book/sh
1.05
Cash/sh
0.88
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
117
IPO
Jun 24, 2008
P/E
16.93
Forward P/E
51.00
PEG
-
P/S
1.32
P/B
1.94
P/C
2.32
P/FCF
35.74
EV/EBITDA
19.29
EV/Sales
0.77
Quick Ratio
4.71
Current Ratio
5.93
Debt/Eq
0.03
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
0.12
EPS next Y
0.04
EPS next Q
-0.02
EPS this Y
-71.67%
EPS next Y
-29.41%
EPS next 5Y
-13.38%
EPS past 3/5Y
- -
Sales past 3/5Y
21.56% 16.91%
EPS Y/Y TTM
-50.75%
Sales Y/Y TTM
-1.94%
EPS Q/Q
-128.03%
Sales Q/Q
-19.99%
Insider Own
34.33%
Insider Trans
0.00%
Inst Own
38.57%
Inst Trans
-5.71%
ROA
9.90%
ROE
13.32%
ROIC
12.14%
Gross Margin
63.86%
Oper. Margin
2.28%
Profit Margin
8.37%
SMA20
-11.23%
SMA50
-22.06%
SMA200
-44.55%
Trades
Shs Outstand
79.03M
Shs Float
52.01M
52W High
7.11 -71.33%
52W Low
1.97 3.55%
Volatility
4.26% 4.97%
ATR (14)
0.12
RSI (14)
35.56
Beta
2.11
Rel Volume
2.04
Avg Volume
504.54K
Volume
1,030,924
Perf Week
-5.12%
Perf Month
-18.40%
Perf Quarter
-35.65%
Perf Half Y
-44.41%
Perf YTD
-67.92%
Perf Year
-70.56%
Perf 3Y
42.66%
Perf 5Y
-64.64%
Perf 10Y
-21.84%
Prev Close
2.01
Price
2.04
Change %
1.49%
Consensus
Strong Buy
Avg. Price Target
$10.67
Implied Upside
+423.0%
Analysts8incl. previous ratings
Rating Distribution6 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 27, 2025Initiated
CCanaccord Genuity
Buy$13+537.3%
Aug 16, 2022Downgrade
OPY logoOOppenheimer
Outperform → Perform
Aug 11, 2022Downgrade
RILY logoRB. Riley Securities
Buy → Neutral$6 → $2.40+17.6%
Mar 08, 2022Initiated
RROTH Capital
Buy$7+243.1%
Oct 16, 2019Initiated
OPY logoOOppenheimer
Outperform$6+194.1%
Feb 14, 2019Initiated
BB. Riley FBR
Buy$7+243.1%
Nov 27, 2017Resumed
HH.C. Wainwright
Buy$6 → $8+292.2%
Sep 25, 2017Initiated
LLadenburg Thalmann
Buy$7+243.1%
Jan 03, 2017Initiated
RRodman & Renshaw
Buy$6+194.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fried Robert NChief Executive OfficerApr 24 '26Option Exercise2.6120,00052,2001,058,981Apr 27 08:33 AM
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, Analytical Reference Standards and Services, and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The Pharmaceuticals segment focuses on the pharmaceutical development of NAD precursor portfolio for potential therapeutic applications in rare diseases. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Co-Founder & ChairmanMr. Frank Louis Jaksch Jr.
CEO & DirectorMr. Robert N. Fried
CFO & Principal Accounting OfficerMr. Ozan Pamir C.F.A.
Senior VP & General CounselMr. Carlos Lopez
Senior Vice President of Global Regulatory & Scientific AffairsDr. Andrew Shao Ph.D.